SSA
BMY icon

Schonfeld Strategic Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,000
Closed -$303K – 2635
2026
Q1 		$303K Buy
+5,000
New +$291K ﹤0.01% 1576
2024
Q2 		– Sell
-150,000
Closed -$8.13M – 2167
2024
Q1 		$8.13M Buy
+150,000
New +$7.64M 0.05% 454

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Schonfeld Strategic Advisors's BMY Position: Q2 2026 in Review

Schonfeld Strategic Advisors reduced its Bristol-Myers Squibb (BMY) stake by 94% in Q2 2026, selling an estimated $8.41M and leaving 8,937 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #2164.

Schonfeld Strategic Advisors first reported a position in BMY in Q1 2016 and has held it in 37 quarters since. The position peaked at $52.9M in Q3 2025. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Schonfeld Strategic Advisors held 8,937 shares of Bristol-Myers Squibb worth $214K as of Q2 2026.
  • Schonfeld Strategic Advisors sold 146,481 Bristol-Myers Squibb shares in Q2 2026, an estimated $8.41M.
  • Bristol-Myers Squibb made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2164 holding.
  • Schonfeld Strategic Advisors first reported a position in Bristol-Myers Squibb in Q1 2016 and has held it in 37 quarters since.
  • Schonfeld Strategic Advisors's Bristol-Myers Squibb position peaked at $52.9M in Q3 2025.
  • 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.